VVOS

Vivos Therapeutics, Inc.
CAPPED RATING

Vivos Therapeutics, Inc. (VVOS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (F). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA -0.7
Rev Growth YoY 34.9%
Gross Margin 61.9%
Price Return 3M -67.4%
Price Return 12M -96.1%
Catalyst Signal 0.00
Market Cap $3.3M
TTM Revenue $20.9M
Price / Sales 0.2
ROE N/M

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) B (3.3) D+ (1.8) F (0.5) C+ (2.6) C (2.3)
2026-11-08 B- (3.0) B (3.4) D+ (1.8) F (0.5) C+ (2.6) C (2.3)
2026-11-01 B- (3.0) B (3.3) D+ (1.8) F (0.4) C+ (2.7) C (2.2)
2026-10-25 B- (3.0) B (3.3) D+ (1.8) F (0.4) C+ (2.6) C (2.2)
2026-10-18 B- (3.0) B (3.3) D+ (1.8) F (0.5) C+ (2.6) C (2.2)
Page 1 of 4